FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy

SPOTLIGHT: Novartis plans Phase III trial


Vectura is touting an announcement from Novartis that it will begin a late-stage trial of a new COPD therapy in 2007 that incorporates a drug Vectura developed. Novartis expects to ask for marketing approval of QVA149--a combinatorial therapy--in 2010. Report


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceBiotech Email Newsletter:
Be the first to comment
More stories about Drug Trials   sales and marketing   Novartis   COPD  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.